( RALEIGH N.C.--(BUSINESS WIRE)--May 17...)Salix Pharmaceuticals Previews Digestive Disease Week 2007,Health

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of 18 investigator-initiated trials related to the Company's products will be presented at Digestive Disease Week(R) 2007, which will be held May 19-24, 2007. Digestive Disease Week is considered the largest and most prestigious meeting in the world for the GI professional. Every year it attracts more than 16,000 physicians, researchers and academics from around the world who desire to stay up-to-date in their respective fields. The meeting is the year's best opportunity to learn about the latest advances in gastroenterology, hepatology, endoscopy and gastrointestinal surgery; prevention, diagnosis and treatment of digestive disorders; and cutting-edge technological advances.

POSTER PRESENTATIONS: -0-

TOPIC                                        LEAD AUTHOR        DATE

---------------------------------------- -------------------- --------


XIFAXAN

An open label series of rifaximin for     A. Kornbluth, M.D.   May 20

 long term maintenance therapy for

 patients with refractory pouchitis


History of hypothyroidism is associated   E. Lauritano, M.D.   May 20

 to small intestinal bacterial

 overgrowth


High dosage rifaximin for the treatment  E. Scarpellini, M.D.  May 20

 of small intestinal overgrowth


High recurrence of small intestinal       E. Lauritano, M.D.   May 20

 bacterial overgrowth after antibiotic


Rifaximin versus systemic antibiotics     M. Gabrelli, M.D.    May 20

 for the treatment of small bowel

 bacterial overgrowth


Small intestinal bacterial overgrowth in   A. Parodi, M.D.     May 20

 acromegalic patients


May breath test be useful in diagnosis     A. Parodi, M.D.     May 20

 of IBS patients? an Italian Study


The oral nonsystemic antibiotic            H. DuPont, M.D.     May 20

 rifaximin prevents symptom recurrence

 in patients with recurrent C.

 difficile-associated diarrhea


Characterization o
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of
Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies